The Senate Health, Education, Labor and Pensions Committee held its second hearing on healthcare spending Tuesday, with lawmakers and witnesses trying to drill down on big questions that could lead to concrete health policy.
UnitedHealth Group saw revenue climb 13.3% in the first quarter of 2018 over the prior-year period. What does Q2 have in store?
Foxconn and the newly formed Advocate Aurora Health announced a technology partnership Thursday to gather Foxconn employees' data to lower their healthcare costs and improve their health. If it works, they plan to expand the venture.
Health systems are putting leading-edge digital tools to the test by applying them to mundane administrative tasks, which machines are more suited for anyway.
It's no surprise that labor costs are top of mind for chief financial officers. But with historically low unemployment numbers, that budget line item looms even larger as organizations try to figure out new strategies to not just recruit, but, more importantly, retain workers.
The growing availability of personalized estimator tools makes it harder for hospitals to argue they shouldn't be required to publish prices, as the CMS wants.
The House Veterans' Affairs Committee begins what is likely to be a long oversight process of Cerner's hefty contract to modernize the VA's electronic health record system.
In an aim to solicit the most competitive bid for goods or services, healthcare organizations frequently issue a traditional Request for Proposal, or RFP, to various vendors. While a traditional RFP may get you the best price on that shiny new CT scanner or beds for your new hospital wing, it may...
Emergency department spending per member nearly doubled from 2009 to 2016 as the severity of ED visits and the prices associated with those visits increased, new data from the Health Care Cost Institute shows.
Drugmakers have worked hard to blame the 340B program for skyrocketing drug prices, but no amount of misdirection can overcome mounting evidence that drug prices are the root of the problem, Dr. Bruce Siegel says.
Unless Congress changes the law or the FDA changes guidance on biosimilar development, patients and payers can expect to pay exorbitant prices for biologics long after the drugs' patents have expired.
Commentary: Trump's proposals on drug prices are right to focus on anti-competitive market practices
There are proposals in President Donald Trump's plan that if implemented could ensure stronger competition from generic and biosimilar medicines and thereby increase access and provide financial relief for patients at the pharmacy counter.